Results of Phase Ii Study of Combined Immunotherapy With Rituximab Plus Lymphokine-Activated Killer Cells as Maintenance in Follicular Lymphoma Patients

Hematological Oncology - United Kingdom
doi 10.1002/hon.192_2631

Related search